USFDA supports remdesivir, first medication to treat Covid-19 patients

USFDA supports remdesivir, first medication to treat Covid-19 patients

Overview

  • Post By : Kumar Jeetendra

  • Source: ANI

  • Date: 23 Oct,2020

Washington: The United States Food and Drug Administration (FDA) has approved Remdesivir for the treatment of coronavirus, Al Jazeera reported citing a statement issued by Gilead Sciences, Inc..

Based on the press release by the company, previously authorised by the FDA for just emergency use to deal with Covid-19 patients, Veklury or Remdesivir is now the first and only accepted Covid-19 treatment in america.

“This approval is based on three randomized controlled trials including the recently published, final results of the National Institute of Allergy and Infectious Diseases’ (NIAID) double blind, placebo-controlled Phase 3 ACTT-1 trial, which showed that treatment with Veklury resulted in clinically meaningful improvements across multiple outcome assessments compared with placebo in hospitalized patients with Covid-19. Based on the strength of these data, Veklury has become a standard of care for the treatment of Covid-19 in hospitalized patients,” Gilead Sciences, Inc said.

The medication was also recently touted by US President Donald Trump, whose physician confirmed he received it at Walter Reed National Military Medical Center as part of his own treatment for Covid-19 earlier this month, Al Jazeera said. The trial was completed in more than 400 hospitals in 30 countries.

Based on the latest update by the Johns Hopkins University, globally 41,536,126 people have tested positive for coronavirus and 1,134,981 deaths have been reported so far.

About Author